

Umecrine Cognition CEO Magnus Doverskog to present at Vator Securities Healthcare Innovation Summit

STOCKHOLM. Umecrine Cognition announced today that CEO Magnus Doverskog will present at Healthcare Innovation Summit on October 7, 2021. Vator Securities Healthcare Innovation Summit is a digital investor event including some of the most innovative and fastest growing companies in the healthcare sector. The event will include focused insights into these healthcare companies, including fire side chats and panel discussions with experts within healthcare and healthcare investments.

The event takes place on October 7 and will be live streamed from Epicenter Stockholm. Apart from Umecrine Cognition, companies such as Immunovia, Mentice, Cyxone, Empros Pharma, Scandion Oncology, SciBase, Moberg Pharma, CombiGene, Magle Chemoswed, Active Biotech, Sinfonia Biotherapeutics, SenzaGen, Sprint Bioscience, AlzeCure Pharma and Alligator Bioscience will present.

CEO Magnus Doverskog, will present at 09:40 – 10:00 including Q&A.

After the companies' presentations there will be a panel discussion with well-known investors and experts in their field.

All presentations are held in English to facilitate participation by foreign investors and companies.

Register for the event at: <https://vatorsecurities.se/event/vator-securities-healthcare-innovation-summit/>

For further information, please contact:

Magnus Doverskog, CEO, Umecrine Cognition AB
Phone: +46 (0)730 39 20 52, e-mail: magnus.doverskog@umecrine.se

About Umecrine Cognition AB

Umecrine Cognition is developing a potential therapy that represents a new target class relevant for several major CNS-related disorders. The lead compound golexanolone (aka GR3027) presently in clinical development is positioned primarily as a novel therapy for the treatment of hepatic encephalopathy in patients with cirrhosis and considered for other CNS-related disorders. For more information, please visit www.umecrinecognition.com.